celldeath

The site to learn about all things apoptosis.

[La Trobe Institute for Molecular Science @LIMSLTU]

🔬 New research from @ONJCRI & LIMS shows the protein BECLIN1 helps protect the gut from inflammation. The findings could lead to new ways to identify people at higher risk of IBD and develop treatments to better protect patients. Read 👉 https://t.co/n6r2vNyMxg
#IBD #latrobe

[celldeath @bcl2_celldeath]

@Dr_Perreault Kk - rest my feet

[La Trobe Institute for Molecular Science @LIMSLTU]

New research by LIMS & @ONJCRI scientists A/Prof Erinna Lee and A/Prof Doug Fairlie has identified a protein which is integral to gut health - a new important lead in the search for a treatment for Inflammatory Bowel Disease. Read more: https://t.co/dlgp4VJtp5

#medtwitter

[celldeath @bcl2_celldeath]

Team @WEHI_research show in @BloodAdvances BCL-XL inhibition kills inflammatory neutrophils and ameliorated associated tissue pathology whilst sparing circulating neutrophils.

See more of the latest BCL-2 papers at https://t.co/YmzfOB5CQx

[celldeath @bcl2_celldeath]

Interesting new NMR structure in @embojournal by Bo OuYang and team of the BAX core domain in a lipid bicelle provides a new model for the mitochondrial apoptotic pore.

See more of the latest BCL-2 papers at https://t.co/YmzfOB5CQx

[celldeath @bcl2_celldeath]

New paper in @PNASNews from Tyler Jacks, @DrTonyLetai and team shows extent of mito priming determines cell fate upon p53 restoration - high -> apoptosis, low -> cell cycle arrest.

See more of the latest BCL-2 papers at https://t.co/YmzfOB5CQx

[celldeath @bcl2_celldeath]

Team from @abbvie led by Andy Souers report in @MCT_AACR pro-drug version of Venetoclax increases solubility & tablet drug loading and reduces food effect to potentially improve oral delivery.
See more of the latest BCL-2/intrinsic apoptosis papers at https://t.co/YmzfOB5CQx

[celldeath @bcl2_celldeath]

New paper in @CD_AACR shows low dose Navitoclax combined with Venetoclax (and chemo) enables BCL-XL and BCL-2 co-targeting without thrombocytopenia in ALL. From Wendy Stock and team @UChicagoMed.

See more of the latest BCL-2 papers at https://t.co/YmzfOB5CQx

[celldeath @bcl2_celldeath]

Another nice paper from @AstraZenecaUS on using their CDK9 inhibitor to overcome resistance to BH3-mimetics in lymphoma. Out now in @BloodJournal .

Keep up with the latest BCL-2 paper at https://t.co/YmzfOB5CQx.

[celldeath @bcl2_celldeath]

Some excellent BH3-mimetics papers out this week including a personal plug for one from my lab in Cell Death Discovery @cddpress looking at the latest AstraZeneca BCL-XL/BCL-2 inhibitor, AZD0466, in mesothelioma.

See more at https://t.co/YmzfOB5CQx.

[celldeath @bcl2_celldeath]

@apoptosislab @MitosRUs Ha! Thanks! Labs definitely skewed & happy to take suggestions (should have Bcl-2 focus though). Classic papers were based on web of science citations (most have >800) though some on important gene discoveries with smaller numbers were included. Will include more in the future..

[celldeath @bcl2_celldeath]

Check out new paper from Andrew Wei and team @ACBDresearch @WEHI_research in @BloodJournal on how Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.

For more of the latest BCL-2-related papers go to https://t.co/CeQQDV9UYs

[celldeath @bcl2_celldeath]

Want to know more about the intrinsic apoptosis / BCL-2 pathway? Go to https://t.co/tl1r5enCu4. See every new paper - updated daily, every lab, historic timeline and classic papers, plus other resources such as cell death journals, conferences and societies.